keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal b vaccine

keyword
https://www.readbyqxmd.com/read/28222677/molecular-characterization-of-invasive-capsule-null-neisseria-meningitidis-in-south-africa
#1
Karistha Ganesh, Mushal Allam, Nicole Wolter, Holly B Bratcher, Odile B Harrison, Jay Lucidarme, Ray Borrow, Linda de Gouveia, Susan Meiring, Monica Birkhead, Martin C J Maiden, Anne von Gottberg, Mignon du Plessis
BACKGROUND: The meningococcal capsule is an important virulence determinant. Unencapsulated meningococci lacking capsule biosynthesis genes and containing the capsule null locus (cnl) are predominantly non-pathogenic. Rare cases of invasive meningococcal disease caused by cnl isolates belonging to sequence types (ST) and clonal complexes (cc) ST-845 (cc845), ST-198 (cc198), ST-192 (cc192) and ST-53 (cc53) have been documented. The clinical significance of these isolates however remains unclear...
February 21, 2017: BMC Microbiology
https://www.readbyqxmd.com/read/28213046/splenectomy-as-a-destination-improving-quality-of-care-among-asplenic-veterans-through-a-travel-clinic
#2
Aaron P Mitchell, Joel C Boggan, Karen Lau, David L Simel
BACKGROUND: Asplenic patients are at risk for severe infections, but adherence to recommended preventive education and vaccination is poor. The goal of this study was to demonstrate that a targeted intervention can improve vaccination rates in a population of asplenic veterans. METHODS: Surgically asplenic patients actively receiving care in our health care system were identified via a database search. Patients were contacted via mailed letters and encouraged to attend an existing travel clinic with a new process designed for asplenic patients...
February 14, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28196734/bactericidal-activity-of-sera-from-adolescents-vaccinated-with-bivalent-rlp2086-against-meningococcal-serogroup-b-outbreak-strains-from-france
#3
Muhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, Ala-Eddine Deghmane, Lubomira Andrew, Li Hao, Thomas R Jones, Lisa K McNeil, Robert E O'Neill, John L Perez, Kathrin U Jansen, Annaliesa S Anderson
OBJECTIVES: Bivalent rLP2086 (Trumenba®; MenB-FHbp), composed of two factor H binding proteins (FHbps), is a vaccine approved in the United States for prevention of Neisseria meningitidis serogroup B (MnB) invasive meningococcal disease (IMD). Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 was assessed against MnB isolates from recent disease outbreaks in France. METHODS: MnB isolates from IMD cases were characterized by whole genome sequencing and FHbp expression was assessed using a flow cytometry-based assay...
February 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28194210/recommended-immunization-schedule-for-children-and-adolescents-immunization-guideline-8th-edition-released-by-the-korean-pediatric-society-in-2015
#4
REVIEW
Jong-Hyun Kim, Eun Hwa Choi, Su Eun Park, Yae-Jean Kim, Dae Sun Jo, Yun-Kyung Kim, Byung-Wook Eun, Jina Lee, Soo-Young Lee, Hyunju Lee, Ki Hwan Kim, Kyung-Hyo Kim
This report includes the recommended immunization schedule table for children and adolescents based on the 8th (2015) and revised 7th (2012) Immunization Guidelines released by the Committee on Infectious Diseases of the Korean Pediatric Society (KPS). Notable revised recommendations include: reorganization of the immunization table with a list of vaccines on the vertical axis and the corresponding age on the horizontal axis; reflecting the inclusion of Haemophilus influenzae type b vaccine, pneumococcal conjugate vaccine, and hepatitis A vaccine into the National Immunization Program since 2012; addition of general recommendations for 2 new Japanese encephalitis (JE) vaccines and their interchangeability with existing JE vaccines; addition of general recommendations for quadrivalent meningococcal conjugate vaccines and scope of the recommended targets for vaccination; and emphasizing catch-up immunization of Tdap vaccine...
December 2016: Korean Journal of Pediatrics
https://www.readbyqxmd.com/read/28192234/meningococcal-carriage-in-dutch-adolescents-and-young-adults-a-cross-sectional-and-longitudinal-cohort-study
#5
Mariëtte B van Ravenhorst, Merijn W Bijlsma, Marlies A van Houten, Veerle M D Struben, Annaliesa S Anderson, Joseph Eiden, Hao Li, Kathrin U Jansen, Hal Jones, Nicholas Kitchin, Louise Pedneault, Elisabeth A M Sanders, Arie van der Ende
OBJECTIVES: Current information on rates and dynamics of meningococcal carriage is essential for public health policy. This study aimed to determine meningococcal carriage prevalence, its risk factors and duration in the Netherlands, where meningococcal C vaccine coverage is >90%. Several methods to identify serogroups of meningococcal carriage isolates among adolescent and young adults were compared. METHODS: Oropharyngeal swabs from 1715 subjects 13-23 years of age were collected in 2013-2014; 300 were prospectively followed over 8 months...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28167517/the-need-to-optimize-adolescent-immunization
#6
Henry H Bernstein, Joseph A Bocchini
The adolescent period heralds the pediatric patient's transition into adulthood. It is a time of dynamic development during which effective preventive care measures can promote safe behaviors and the development of lifelong health habits. One of the foundations of preventive adolescent health care is timely vaccination, and every visit can be viewed as an opportunity to update and complete an adolescent's immunizations.In the past decade, the adolescent immunization schedule has expanded to include 2 doses of quadrivalent meningococcal conjugate vaccine, 1 dose of tetanus, diphtheria, acellular pertussis, absorbed vaccine, 2 or 3 doses of human papillomavirus vaccine, depending on the child's age, and an annual influenza vaccine...
February 6, 2017: Pediatrics
https://www.readbyqxmd.com/read/28158417/meningococcal-carriage-evaluation-in-response-to-a-serogroup-b-meningococcal-disease-outbreak-and-mass-vaccination-campaign-at-a-college-rhode-island-2015-2016
#7
Heidi M Soeters, Melissa Whaley, Nicole Alexander-Scott, Koren V Kanadanian, Jessica R MacNeil, Stacey W Martin, Lucy A McNamara, Kenneth Sicard, Cynthia Vanner, Jeni Vuong, Xin Wang, Utpala Bandy, Manisha Patel
No abstract text is available yet for this article.
February 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28146198/-meningococcal-invasive-disease-caused-by-serogroup-b-in-two-chilean-children-vaccinated-against-acwy-serogroups
#8
Rodolfo Villena, Josefa González
Invasive meningococcal disease (IMD) by serogroup W has become predominant in Chile since 2012, prompting vaccination with conjugate ACWY. We reported two pediatric cases in patients already vaccinated, which evolved with IMD by serogroup B. This should remind us to keep the alertness with this pathology, despite the current vaccination system in Chile, emphasizing in improve our epidemiological case definition and its diagnosis.
December 2016: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
https://www.readbyqxmd.com/read/28140784/the-prevalence-serogroup-distribution-and-risk-factors-of-meningococcal-carriage-in-adolescents-and-young-adults-in-turkey
#9
Rahmi Tuna Tekin, Ener Cagri Dinleyici, Mehmet Ceyhan, Adem Karbuz, Nuran Salman, Murat Sutçu, Zafer Kurugol, Yasemin Balliel, Melda Celik, Mustafa Hacimustafaoglu, Necdet Kuyucu, Meda Kondolot, Gülnar Sensoy, Ozge Metin, Soner Sertan Kara, Meltem Dinleyici, Omer Kılıç, Cihangul Bayhan, Venhar Gurbuz, Emre Aycan, Aygun Memedova, Arzu Karli, Gulçin Bozlu, Solmaz Celebi
The serogroup epidemiology of invasive meningococcal disease (IMD), which varies considerably by geographic region and immunization schedule, changes continuously. Meningococcal carriage data are crucial for assessing IMD epidemiology and designing f potential vaccination strategies. Meningococcal seroepidemiology in Turkey differs from that in other countries: serogroups W and B are the predominant strains for IMD during childhood, whereas no serogroup C cases were identified over the last 10 years and no adolescent peak for IMD was found...
January 31, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28137280/high-dimensional-assessment-of-b-cell-responses-to-quadrivalent-meningococcal-conjugate-and-plain-polysaccharide-vaccine
#10
Daniel O'Connor, Elizabeth A Clutterbuck, Amber J Thompson, Matthew D Snape, Maheshi N Ramasamy, Dominic F Kelly, Andrew J Pollard
BACKGROUND: Neisseria meningitidis is a globally important cause of meningitis and septicaemia. Twelve capsular groups of meningococci are known, and quadrivalent vaccines against four of these (A, C, W and Y) are available as plain-polysaccharide and protein-polysaccharide conjugate vaccines. Here we apply contemporary methods to describe B-cell responses to meningococcal polysaccharide and conjugate vaccines. METHODS: Twenty adults were randomly assigned to receive either a meningococcal plain-polysaccharide or conjugate vaccine; one month later all received the conjugate vaccine...
January 30, 2017: Genome Medicine
https://www.readbyqxmd.com/read/28124080/serologic-response-to-meningococcal-vaccination-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-chronically-treated-with-the-terminal-complement-inhibitor-eculizumab
#11
Ferras Alashkar, Colin Vance, Dörte Herich-Terhürne, Nicole Preising, Ulrich Dührsen, Alexander Röth
Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on eculizumab are susceptible to Neisseria meningitidis infections. The two mainstays to reduce the risk of infection are vaccination and antibiotic prophylaxis. In this retrospective study, serologic response was analyzed after vaccination with a meningococcal vaccine in 23 PNH patients (median age 36 years; range 25 - 88 years; 15 males, 8 females) by measuring serum bactericidal assay (SBA) using rabbit complement (rSBA) titers against meningococcal serogroups A, C, W, and Y...
January 26, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28121236/rapid-response-to-a-college-outbreak-of-meningococcal-serogroup-b-disease-nation-s-first-widespread-use-of-bivalent-rlp2086-vaccine
#12
Theresa M Fiorito, Suzanne Bornschein, Alysia Mihalakos, Catherine M Kelleher, Nicole Alexander-Scott, Koren V Kanadanian, Patricia Raymond, Kenneth Sicard, Penelope H Dennehy
OBJECTIVE: To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B (MenB) disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are < 3 days apart. PARTICIPANTS: Staff, faculty, and students at College X eligible for vaccination. METHODS: An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated...
January 25, 2017: Journal of American College Health: J of ACH
https://www.readbyqxmd.com/read/28100432/effectiveness-and-impact-of-a-reduced-infant-schedule-of-4cmenb-vaccine-against-group-b-meningococcal-disease-in-england-a-national-observational-cohort-study
#13
Sydel R Parikh, Nick J Andrews, Kazim Beebeejaun, Helen Campbell, Sonia Ribeiro, Charlotte Ward, Joanne M White, Ray Borrow, Mary E Ramsay, Shamez N Ladhani
BACKGROUND: In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation programme. A reduced two-dose priming schedule was offered to infants at 2 months and 4 months, alongside an opportunistic catch-up for 3 month and 4 month olds. 4CMenB was predicted to protect against 73-88% of MenB strains. We aimed to assess the effectiveness and impact of 4CMenB in vaccine-eligible infants in England...
December 3, 2016: Lancet
https://www.readbyqxmd.com/read/28099125/meningococcal-acwy-vaccine-uptake-and-awareness-among-student-freshers-enrolled-at-northern-ireland-universities
#14
Peter J A Moore, B Cherie Millar, John E Moore
A new MenACWY conjugate meningococcal vaccination programme was introduced in Northern Ireland (NI) in August 2015, for 13-18 year olds, as well as for first-time university entrants up to 25 years. This reflected the response made by Public Health England, due to the recent rapid increase of meningococcal group W (MenW) disease and on advice of the UK Joint Committee on Vaccination and Immunisation (JCVI). The aims of this study were to evaluate (i) the uptake of the MenACWY vaccine among first-time university students, (ii) vaccine and meningitis awareness, (iii) optimal communication modalities via a multidisciplinary team (MDT) model and (iv) current international vaccination policies relating to non-UK students...
January 18, 2017: International Journal of Adolescent Medicine and Health
https://www.readbyqxmd.com/read/28072958/-investigation-on-immunization-program-coverage-rate-and-its-safety-in-children-with-tuberous-sclerosis
#15
Y Gao, L P Zou, M N Zhang, L Y Pang, Y Y Wang, S F Ma, L L Huang
Objective: To investigate the status of immunization of National Immunization Program (NIP) and its adverse reaction rate in children with tuberous sclerosis. Method: Questionnaire survey was adopted to identify the vaccination coverage and its adverse events; 72 cases of children with tuberous sclerosis and 78 normal controls (healthy children completing age-appropriate NIP) admitted to Chinese People's Liberation Army General Hospital from December 2014 to November 2015 were involved into this study. Result: The age-appropriate NIP coverage rate of tuberous sclerosis was 36%(26/72)...
January 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/28038948/-immunisation-schedule-of-the-spanish-association-of-paediatrics-2017-recommendations
#16
David Moreno-Pérez, Francisco José Álvarez García, Javier Arístegui Fernández, María José Cilleruelo Ortega, José María Corretger Rauet, Nuria García Sánchez, Ángel Hernández Merino, Teresa Hernández-Sampelayo Matos, Manuel Merino Moína, Luis Ortigosa Del Castillo, Jesús Ruiz-Contreras
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV- AEP) annually publishes the immunisation schedule which, in our opinion, is considered optimal for children resident in Spain, taking into account the evidence available on current vaccines. Pneumococcal and varicella immunisation in early childhood is already included in all funded vaccines present in the regional immunisation programmes. Furthermore, this committee establishes recommendations on vaccines not included in official calendars (non-funded immunisations), such as rotavirus, meningococcal B, and meningococcal ACWY...
February 2017: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/28029540/use-of-a-booster-dose-of-capsular-group-c-meningococcal-glycoconjugate-vaccine-to-demonstrate-immunologic-memory-in-children-primed-with-one-or-two-vaccine-doses-in-infancy
#17
David Pace, Ameneh Khatami, Simon Attard-Montalto, Merryn Voysey, Adam Finn, Saul N Faust, Paul T Heath, Ray Borrow, Matthew D Snape, Andrew J Pollard
BACKGROUND: Use of a polysaccharide vaccine challenge to demonstrate immunologic memory after priming with capsular group C meningococcal conjugate vaccines (MenCC) risks induction of immunologic hyporesponsiveness. For this reason, MenCC vaccines are now used as probes of immunologic memory, however, no studies have demonstrated their ability to distinguish primed from unprimed children. METHODS: This study was part of a randomised controlled trial investigating the immunogenicity of a booster dose of the combined Haemophilus influenzae type b and MenC-tetanus toxoid vaccine (Hib-MenC-TT) in infants receiving reduced dose MenCC vaccine priming schedules (one MenC-CRM/MenC-TT or two MenC-CRM vaccine doses) compared with an unprimed group...
October 28, 2016: Vaccine
https://www.readbyqxmd.com/read/28008331/a-meningococcal-outer-membrane-vesicle-vaccine-incorporating-genetically-attenuated-endotoxin-dissociates-inflammation-from-immunogenicity
#18
David J Dowling, Holly Sanders, Wing Ki Cheng, Sweta Joshi, Spencer Brightman, Ilana Bergelson, Carlo Pietrasanta, Simon D van Haren, Sandra van Amsterdam, Jeffrey Fernandez, Germie P J M van den Dobbelsteen, Ofer Levy
BACKGROUND: Group B Neisseria meningitidis, an endotoxin-producing Gram-negative bacterium, causes the highest incidence of group B meningococcus (MenB) disease in the first year of life. The Bexsero vaccine is indicated in Europe from 8 weeks of age. Endotoxin components of outer membrane vesicles (OMVs) or soluble lipopolysaccharide (LPS) represent a potential source of inflammation and residual reactogenicity. The purpose of this study was to compare novel candidate MenB vaccine formulations with licensed vaccines, including Bexsero, using age-specific human in vitro culture systems...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27960595/meningococcal-serogroup-b-vaccines-estimating-breadth-of-coverage
#19
Robert G K Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R Jones, Shannon L Harris, John L Perez, Joseph J Eiden, Kathrin U Jansen, Annaliesa S Anderson
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging. While capsular polysaccharide conjugate vaccines have been highly successful in the prevention of disease due to meningococcal serogroups A, C, W, and Y, this approach has not been possible for MenB owing to the poor immunogenicity of the MenB capsular polysaccharide. Vaccines based on outer membrane vesicles have been successful in the prevention of invasive MenB disease caused by the single epidemic strain from which they were derived, but they do not confer broad protection against diverse MenB strains...
February 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27939054/concomitant-administration-of-a-fully-liquid-ready-to-use-dtap-ipv-hb-prp-t-hexavalent-vaccine-with-a-meningococcal-serogroup-c-conjugate-vaccine-in-infants
#20
Timo Vesikari, Ray Borrow, Xavier Da Costa, Patrick Richard, Cécile Eymin, Florence Boisnard, Stephen Lockhart
DTaP-IPV-HB-PRP-T or hexavalent vaccines are indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The present study evaluates the safety and immunogenicity of a ready-to-use hexavalent vaccine when co-administered with a meningococcal serogroup C conjugate (MenC) vaccine in infants. This was a phase III, open-label, randomised, multicentre study conducted in Finland...
January 11, 2017: Vaccine
keyword
keyword
61786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"